Press releases by members


16 May 2019
On May 28th and 29th, representatives of the European Commission will visit BDI Biotechnology to begin evaluation of the European project, LIFE YEAST. BIOTECHNOLOGY DEVELOPMENT FOR INDUSTRY
On May 28th and 29th, representatives of the European Commission will visit BDI Biotechnology to begin evaluation of the European project, LIFE YEAST. In the coming days, members of the European Commission and representatives of The LIFE Program, will visit the facilities of BDI Biotechnology, located in the Boecillo Technology Park.
  View more
7 May 2019
Two UB centers create a new platform on neurotoxicology and drug testing based on stem cells Parc Científic de Barcelona (PCB)
Two UB centers create a new platform on neurotoxicology and drug testing based on stem cells The Production and Validation Center for Advanced Therapies (Creatio) and the Research Centre on Toxicology (CERETOX) –through the Unit of Experimental Toxicology and Ecotoxicology (UTOX) from the Barcelona Science Park (PCB–, entities of the University of Barcelona with the Tecnio seal, have created the platform Avantdrug.
  View more
16 April 2019
Esteve's R&D&I has once again received the qualification ''Excellent'' in the Profarma program Parc Científic de Barcelona (PCB)
Esteve's R&D&I has once again received the qualification ''Excellent'' in the Profarma program Once again, Esteve's research activity has received the qualification ''Excellent'' in the 2018 call of the Profarma program, resolved by the Spanish Ministry of Industry, Commerce and Tourism.
  View more
9 April 2019
ALGAE4CONTROL Project on bio-pesticides BIORIZON BIOTECH, S.L.
ALGAE4CONTROL Project on bio-pesticides Almeria biotechnology company Biorizon Biotech leads a research consortium along with the University of Almeria and Cajamar Foundation.The aim is to develop biopesticides from microalgae within the framework of the ALGAE4CONTROL Project.
  View more
4 April 2019
CENER is developing technology for future urban biorefineries, to move towards a circular bioeconomy CENER, BIO2C – Biorefinery and Bioenergy Centre
CENER is developing technology for future urban biorefineries, to move towards a circular bioeconomy CENER is involved in 4 specific initiatives, in order to develop the most adequate management and valorization routes of different urban biowastes
  View more
21 March 2019
Enantia develops an innovative Cannabinoids Cocrystal Platform Parc Científic de Barcelona (PCB)
Enantia develops an innovative Cannabinoids Cocrystal Platform Enantia, a company with headquarters in the Barcelona Science Park and specialised in R&D process chemistry, solid form development and medicinal chemistry, has again succeeded in applying cocrystallisation technology to a new family of compounds: the cannabinoids.
  View more
13 March 2019
BIOSEARCH LIFE COMMITS TO HEALTHY GESTATION AND LACTATION THROUGH THE MODULATION OF THE MICROBIOTA IN WOMEN Biosearch S.A.
BIOSEARCH LIFE COMMITS TO HEALTHY GESTATION AND LACTATION THROUGH THE MODULATION OF THE MICROBIOTA IN WOMEN The research addresses the search for innovative solutions to prevent and/or treat women's health problems during the pre-conceptive stage, pregnancy and lactation through the study of their microbiota and the use of probiotic strategies aimed at avoiding or reducing microbiota imbalances.
  View more
12 March 2019
Análisis prenatales no invasivos al alcance de todos medmesafe
Análisis prenatales no invasivos al alcance de todos • medmesafe.com, la primera plataforma online de medicina predictiva basada en la genética, facilita la detección de enfermedades como el Síndrome de Down a partir de la décima semana de embarazo gracias al test q-NIPT.
  View more
12 March 2019
Sello de SME europea conseguido. Neurofix sl
Sello de SME europea conseguido. Sello de SME europea conseguido.
Qualification of an enterprise as a micro, small or medium-sized enterprise (SME) for EMA related services only
  View more
8 March 2019
SOM Biotech closes a financing round of €7M Parc Científic de Barcelona (PCB)
SOM Biotech closes a financing round of €7M SOM Biotech, a clinical-stage drug discovery and development company focused on repurposing drugs for orphan diseases of the Central Nervous System headquartered at the Barcelona Science Park, has just closed a financing round of 7 million euros
  View more
5 March 2019
ALGENEX Cierra ronda de financiación y refuerza su equipo de dirección ALGENEX (Alternative Gene Expression S.L.)
ALGENEX Cierra ronda de financiación y refuerza su equipo de dirección ALGENEX SL, una empresa biotecnológica privada centrada en el desarrollo de tecnologías disruptivas para la producción de productos biológicos recombinantes, anuncia hoy el cierre de una ronda de financiación de alrededor de 4M€ y el refuerzo de su equipo de dirección con el nombramiento de Claudia Jiménez como Directora General y Virginia González como Directora Financiera.
  View more
27 February 2019
Kelly Arrontes blends art and science at Barcelona Science Park again Parc Científic de Barcelona (PCB)
Kelly Arrontes blends art and science at Barcelona Science Park again The work “The origin of life” by artist Kelly Arrontes was unveiled yesterday at Barcelona Science Park. The unveiling, presided over by the rector of the University of Barcelona, Joan Elias, brought together a hundred people and leading representatives from the academic, scientific and cultural world and from the Third Social Sector.
  View more
26 February 2019
An Open-Innovation Test Bed for Medical Devices: Kick-off for new EU Research Project TBMED Antares Consulting
26 February 2019 – The new EU research project TBMED aims to support European med-tech companies in global competition by reducing the time-to-market of high-risk medical devices (MD).
  View more
26 February 2019
Cost-effectiveness study of dabigatran versus warfarin and rivaroxaban in patients with advanced age and suffering from non-ventricular atrial fibrillation in Spain BCN HEALTH

1117/5000
BCN HEALTH has published the study "Are cost-effective ACODs in elderly patients? Analysis from the perspective of the National Health System "in the Spanish Journal of Health Economics.
BCN HEALTH developed a cost-effectiveness model to determine the cost to the healthcare system and the effectiveness of dabigatran, warfarin and rivaroxaban for elderly patients (older than 75 years) with non-ventricular atrial fibrillation. In the model, the incremental cost-effectiveness ratio has been used, which is essentially conditioned by the number of clinical events that the patient suffers (stroke, embolism, intracranial hemorrhage and acute myocardial infarction), with its corresponding cost, and by the degree of disability of patients after suffering these events.
The results obtained show that dabigatran is a cost-effective therapy against warfarin and dominant against rivaroxaban, which means that it has lower total costs for the healthcare system and is more effective in relation to the two drugs with which it is compared.
  View more
14 February 2019
Aromics recieves 1 M€ from the European Union to boost its drug against the asbestos-related hallmark cancer Parc Científic de Barcelona (PCB)
Aromics recieves 1 M€ from the European Union to boost its drug against the asbestos-related hallmark cancer Aromics, a biotech company located at the Barcelona Science Park (PCB), has been awarded with 1,085.659€ from the European Union – through the SME instrument of the Horizon 2020 (H2020-EIC-SMEInst-2018-2020-Phase 2)– for the development of the BERMES project, whose objective is the completion of the regulatory preclinics of NAX035, an innovative therapy for the treatment of malignant mesothelioma.
  View more
13 February 2019
GlyCardial Diagnostics moves its headquarters to Barcelona Science Park Parc Científic de Barcelona (PCB)
GlyCardial Diagnostics moves its headquarters to Barcelona Science Park The biotechnological company GlyCardial Diagnostics, focused on the development of a novel diagnostic test for early detection of cardiac ischemia, has joined the Barcelona Science Park (PCB). The company is about to begin a study with patients to validate this innovative and disruptive technology, which could revolutionise hospital clinical practice.
  View more
11 February 2019
Piden autorización para probar medicación en pacientes con lesión de médula espinal Neurofix sl
Piden autorización para probar medicación en pacientes con lesión de médula espinal La empresa biotecnológica Neurofix ubicada en el Parque Científico de la Universidad de Salamanca que desarrolla fármacos para el Sistema Nervioso Central ya ha solicitado a la Agencia Española del Medicamento la autorización para iniciar una fase Clínica para el tratamiento del dolor neuropático en pacientes con lesión de médula espinal
  View more
31 January 2019
Teresa Tarragó, one of the 50 women driving the 'Innovactoras' project Parc Científic de Barcelona (PCB)
Teresa Tarragó, one of the 50 women driving the 'Innovactoras' project Teresa Tarragó, CEO and co-founder of the biotechnology company Iproteos based at Barcelona Science Park (PCB), is participating in Innovactoras, a social project that seeks to raise the profile of female entrepreneurs and innovators known for their work Science, Technology, Business, Education and Society, and make them role models for the next generation.
  View more
31 January 2019
Embryotools achieves the world’s first pregnancy with a new nuclear transfer technique for treating infertility Parc Científic de Barcelona (PCB)
Embryotools achieves the world’s first pregnancy with a new nuclear transfer technique for treating infertility In a pilot clinical trial conducted by the Institute of Life in Athens, researchers from the centre Embryotools —with headquarters in the Barcelona Science Park– have achieved the world’s first pregnancy that uses the Maternal Spindle Transfer technique to solve problems of infertility.
  View more
30 January 2019
M. Miralpeix Pharma Consulting establishes its headquarters at the Barcelona Science Park Parc Científic de Barcelona (PCB)
M. Miralpeix Pharma Consulting establishes its headquarters at the Barcelona Science Park M. Miralpeix Pharma Consulting, specialized in providing scientific and strategic advice to companies and public and private research centres linked to life sciences and healthcare, has opened its headquarters at the Barcelona Science Park.
  View more
29 January 2019
Avances contra el dolor en pacientes con lesión de médula espinal Neurofix sl
Avances contra el dolor en pacientes con lesión de médula espinal Una empresa biotecnológica ubicada en el Parque Científico de la Universidad de Salamanca, que desarrolla fármacos para el sistema nervioso central solicitará el próximo día 9 de febrero a la Agencia Española del Medicamento la autorización para iniciar una fase clínica para un nuevo medicamento para el tratamiento del dolor neuropático en pacientes con lesión de médula espinal.
  View more
15 January 2019
Genesis Ventures Ventures has invested €325,000 in biomedical projects in 2018 Parc Científic de Barcelona (PCB)
Genesis Ventures Ventures has invested €325,000 in biomedical projects in 2018 Genesis Ventures, Ventures fund, managed by Genesis Biomed, –located at the Barcelona Science Park– has invested a total of €325,000 in five start-ups, spin-offs and projects in the biomedical field during its first year of existence. During 2019, 10 new investments will be carried out to complete the first €1.2 million fund.
  View more
4 January 2019
BIOMILK 300, BIOLAN´S LACTOSE ANALYZER IN DAIRY PRODUCTS, OBTAINS EUROFINS VALIDATION BIOLAN MICROBIOSENSORES
BIOMILK 300, BIOLAN´S LACTOSE ANALYZER IN DAIRY PRODUCTS, OBTAINS EUROFINS VALIDATION BIOMILK 300, BIOLAN´s biosensor device for the quantification of LACTOSE in milk and lactose-free dairy products, has achieved a relevant technical recognition thanks to the validation of EUROFINS.
  View more
4 January 2019
OSASEN obtains the Operating License for Medical Devices from the Spanish Agency of Medicines and Medical Devices OSASEN SENSORES, S.L.
OSASEN obtains the Operating License for Medical Devices from the Spanish Agency of Medicines and Medical Devices OSASEN SENSORES, belonging to the BIOLAN group, has recently obtained from the Spanish Agency of Medicines and Medical Devices the Operating License for Medical Devices.
  View more
3 January 2019
CESIF presenta una nueva convocatoria de su oferta formativa de Executive Education Centro de Estudios Superiores de la Industria Farmacéutica
CESIF presenta una nueva convocatoria de su oferta formativa de Executive Education CESIF, Centro de Estudios Superiores de la Industria Farmacéutica, convoca en 2019 nuevas ediciones de sus programas de especialización para profesionales del sector farmacéutico en las áreas de Regulatory Affairs, acceso al mercado, desarrollo de negocio, Project Management y en el entorno digital.
  View more
Developed by Web4Bio